22 U.S. lawmakers have disclosed 67 Novartis Ag trades under the STOCK Act — 43 buys and 24 sells between 2015 and 2026. Congress has been net buyers of NVS, and their disclosed buys are up 20.8% versus the latest close.
*Notional-weighted price return on lawmakers' disclosed buys of NVS, marked to the latest close — per-share (share counts aren't disclosed).
Lawmakers ranked by notional-weighted return on their disclosed NVS buys (last ~3y), marked to the latest close.
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2017-03-16 | James B. Renacci | BUY | $1K–$15K | $67.80 | $151.72 2026-08-13 | +123.8% |
| 2017-01-24 | Peter Welch | BUY | $1K–$15K | $62.75 | $151.72 2026-08-13 | +141.8% |
| 2017-01-23 | James B. Renacci | BUY | $1K–$15K | $62.85 | $151.72 2026-08-13 | +141.4% |
| 2017-01-13 | James B. Renacci | BUY | $1K–$15K | $64.87 | $151.72 2026-08-13 | +133.9% |
| 2016-12-05 | Richard L. Hanna | SELL | $100K–$250K | $61.80 | $151.72 2026-08-13 | -13.6% rt |
| 2016-12-05 | Debbie Dingell | BUY | $1K–$15K | $61.80 | $151.72 2026-08-13 | +145.5% |
| 2016-08-26 | James B. Renacci | BUY | $1K–$15K | $71.07 | $151.72 2026-08-13 | +113.5% |
| 2016-06-08 | James B. Renacci | BUY | $1K–$15K | $72.93 | $151.72 2026-08-13 | +108.0% |
| 2016-03-31 | William Cassidy | BUY | $1K–$15K | $64.91 | $151.72 2026-08-13 | +133.7% |
| 2016-03-31 | William Cassidy | BUY | $1K–$15K | $64.91 | $151.72 2026-08-13 | +133.7% |
| 2016-01-21 | Richard L. Hanna | BUY | $100K–$250K | $71.56 | $151.72 2026-08-13 | +112.0% |
| 2015-12-09 | James B. Renacci | BUY | $1K–$15K | $75.23 | $151.72 2026-08-13 | +101.7% |
| 2015-10-23 | Kenny Marchant | BUY | $1K–$15K | $83.32 | $151.72 2026-08-13 | +82.1% |
| 2015-09-29 | Diane Black | BUY | $1K–$15K | $80.22 | $151.72 2026-08-13 | +89.1% |
| 2015-09-23 | Diane Black | BUY | $1K–$15K | $82.80 | $151.72 2026-08-13 | +83.2% |
| 2015-07-17 | James B. Renacci | BUY | $1K–$15K | $94.81 | $151.72 2026-08-13 | +60.0% |
| 2015-05-15 | James B. Renacci | BUY | $1K–$15K | $92.97 | $151.72 2026-08-13 | +63.2% |
Return: buys marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (stock move after the sale, seller's perspective).
22 members of the U.S. House and Senate have disclosed Novartis Ag transactions under the STOCK Act — 43 purchases and 24 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
No member of Congress has disclosed a NVS purchase in the last 90 days. STOCK Act filings lag the trade by up to 45 days, so newer buys may still be pending disclosure.
Notional-weighted, lawmakers' disclosed NVS buys are up 20.8% versus the latest close of $151.72. Each trade's own return — and realized round-trips on matched sells — is in the Return column.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded NVS and how it performed.